REDWOOD CITY, Calif., Jan. 25, 2011 /PRNewswire/ — Codexis,
Inc. (Nasdaq:
CDXS) today announced the company’s first biocatalysis
collaboration in Japan, with Dainippon Sumitomo Pharma Co., Ltd.
(DSP), one of the ten largest Japanese pharmaceutical
manufacturers.
Under the agreement, Codexis will supply biocatalysis screening
products and services to DSP for use in selected undisclosed
therapeutic products in its development pipeline. Codexis
technology is used by innovator pharmaceutical companies worldwide
to reduce cost, increase manufacturing efficiency and reduce
environmental impact.
“We are very pleased to be entering the Japanese market through
this important collaboration with DSP,” said Joseph Sarret, M.D.,
President, Codexis Pharmaceutical Services and Enzyme Products.
“DSP has identified Codexis technology as a key component in
its drive to develop green, sustainable manufacturing processes to
serve their key markets, and we look forward to a productive
partnership.”
Codexis is a clean technology company. Codexis develops
optimized biocatalysts that make industrial processes faster,
cleaner and more efficient. Codexis’ technology is commercialized
with leading global pharmaceutical companies and in development for
advanced biofuels with Shell. Other potential markets include
carbon capture, water treatment and chemicals. For more
information, see www.codexis.com.
Dainippon Sumitomo Pharma Co., Ltd. is a
multibillion dollar, top ten listed pharmaceutical company in Japan
with a diverse portfolio of pharmaceutical, animal health and food
and specialty products. DSP aims to produce innovative
pharmaceutical products in the CNS field, which has been designated
as the key therapeutic area, and the specialty area, designated as
a frontier therapeutic area. DSP has more
‘/>”/>
